Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella(Parker Institute for Cancer Immunotherapy), Saar Gill(Parker Institute for Cancer Immunotherapy)
Cited by 554
Related Papers
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
|Nature Medicine|2022|308
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
|Cancer Discovery|2020|297
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
|Computational and Structural Biotechnology Journal|2016|281
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
|Nature Medicine|2024|254